JP2023554379A - 組換えｃｄ３結合タンパク質及びそれらの使用 - Google Patents

組換えｃｄ３結合タンパク質及びそれらの使用 Download PDF

Info

Publication number
JP2023554379A
JP2023554379A JP2023536343A JP2023536343A JP2023554379A JP 2023554379 A JP2023554379 A JP 2023554379A JP 2023536343 A JP2023536343 A JP 2023536343A JP 2023536343 A JP2023536343 A JP 2023536343A JP 2023554379 A JP2023554379 A JP 2023554379A
Authority
JP
Japan
Prior art keywords
ankyrin repeat
seq
amino acid
protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554379A5 (https=
Inventor
セバスティアン グリム
ニーナ レシュケ
クリスティアン ライヒェン
ベルント シュレーレス
ヴィクトル レヴィツキー
ラウラ ジャンバール
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2023554379A publication Critical patent/JP2023554379A/ja
Publication of JP2023554379A5 publication Critical patent/JP2023554379A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023536343A 2020-12-16 2021-12-16 組換えｃｄ３結合タンパク質及びそれらの使用 Pending JP2023554379A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063126356P 2020-12-16 2020-12-16
US63/126,356 2020-12-16
EP20216705.2 2020-12-22
EP20216705 2020-12-22
US202163182394P 2021-04-30 2021-04-30
US63/182,394 2021-04-30
PCT/EP2021/086331 WO2022129428A1 (en) 2020-12-16 2021-12-16 Recombinant cd3 binding proteins and their use

Publications (2)

Publication Number Publication Date
JP2023554379A true JP2023554379A (ja) 2023-12-27
JP2023554379A5 JP2023554379A5 (https=) 2024-12-16

Family

ID=79282877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536343A Pending JP2023554379A (ja) 2020-12-16 2021-12-16 組換えｃｄ３結合タンパク質及びそれらの使用

Country Status (9)

Country Link
US (1) US20240052033A1 (https=)
EP (1) EP4263608A1 (https=)
JP (1) JP2023554379A (https=)
KR (1) KR20230120139A (https=)
AU (1) AU2021403658A1 (https=)
CA (1) CA3202296A1 (https=)
IL (1) IL303629A (https=)
MX (1) MX2023007067A (https=)
WO (1) WO2022129428A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065349A2 (en) * 2018-09-28 2020-04-02 The Chancellor, Masters And Scholars Of The University Of Cambridge Vaccines and methods
WO2020245175A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
WO2020245173A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065349A2 (en) * 2018-09-28 2020-04-02 The Chancellor, Masters And Scholars Of The University Of Cambridge Vaccines and methods
WO2020245175A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
WO2020245173A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
""Pioneering a new class of drugs with a broad portfolio and global partnerships"", MOLECULAR PARTNERS, PRESENTATIONS, [ONLINE], JPN6025043882, 9 November 2020 (2020-11-09), ISSN: 0005717908 *
LI, H. ET AL.: ""Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cance", ANTIB. THER., vol. 2, JPN6025043883, 2019, pages 79 - 87, ISSN: 0005717907 *

Also Published As

Publication number Publication date
US20240052033A1 (en) 2024-02-15
KR20230120139A (ko) 2023-08-16
EP4263608A1 (en) 2023-10-25
CA3202296A1 (en) 2022-06-23
IL303629A (en) 2023-08-01
WO2022129428A1 (en) 2022-06-23
MX2023007067A (es) 2023-08-09
AU2021403658A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
JP6783797B2 (ja) 抗がん融合ポリペプチド
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
JP2024513559A (ja) 新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー
JP2024509241A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ
JP2024508969A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
KR20230155464A (ko) 신규한 DARPin-기반 다중특이성 T-세포 인게이저
CN116802213A (zh) 重组cd3结合蛋白及其用途
KR102669477B1 (ko) 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도
WO2024251742A1 (en) Recombinant cd2 binding proteins and their use
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
CN117242100A (zh) 基于DARPin的新型CD70接合物
TW202600600A (zh) Egfr特異性抗原結合蛋白與細胞介素的偶聯物
CN117255803A (zh) 基于DARPin的新型CD33接合物
HK40114315A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
HK40035117B (zh) 抗tigit抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316